Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Comparing Three Catheter Aspiration Strategies for Intermediate-High-Risk Acute Pulmonary Embolism

10 de novembro de 2026 atualizado por: Qiu Jipeng

Safety and Effectiveness of Different-Size Percutaneous Catheter Aspiration Strategies in Patients With Intermediate-High-Risk Acute Pulmonary Embolism: A Prospective, Multicentre, Open-Label Observational Cohort Study

Acute pulmonary embolism (PE) is a serious and potentially life-threatening condition in which blood clots block the arteries of the lungs. For patients with intermediate-high-risk PE, doctors may remove the clots through a thin tube (catheter) placed into the lung arteries, a procedure called percutaneous catheter aspiration.

Two main types of catheters are used. Small-bore catheters (8-12 French) are easier to guide into the smaller, more distant branches of the lung arteries, but they remove large central clots less efficiently. Large-bore catheters (16 French or larger) remove central clots more effectively, but are harder to advance into the smaller branches. Some doctors use both types together, starting with a large-bore catheter for the central clot and then a small-bore catheter for the remaining distal clot. It is not yet known which of these three approaches is safest and works best.

This study will follow about 225 adults with intermediate-high-risk acute PE who are treated with catheter aspiration at five hospitals in China. Participants are grouped according to the catheter strategy that was actually used during their routine care: small-bore aspiration only, large-bore aspiration only, or combined large-bore plus small-bore aspiration. Information is collected from routine hospital tests, CT scans, echocardiograms, procedure records, and follow-up visits at 24 hours, 48 hours, 7 days, 30 days, and 90 days after the procedure. The study does not require any extra invasive tests or procedures.

The main goals are to compare, among the three groups: (1) the rate of major adverse events within 7 days after the procedure, and (2) the improvement in right-heart strain seen on CT scans 48 hours after the procedure. The results may help doctors choose the most suitable catheter strategy for patients with intermediate-high-risk acute PE.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Background Acute pulmonary embolism (PE) is the third leading cause of cardiovascular death worldwide. Patients with intermediate-high-risk PE are haemodynamically stable but have imaging evidence of right ventricular dysfunction and elevated cardiac biomarkers, and remain at risk of early clinical deterioration. Anticoagulation alone may be insufficient to reduce thrombus burden, whereas systemic thrombolysis carries a substantial risk of major bleeding. Percutaneous catheter-based therapy has therefore become an important treatment option. Current aspiration catheters fall into two categories: small-bore systems (8-12 F), which are highly trackable into distal pulmonary artery branches but less efficient at removing large central thrombus, and large-bore systems (16 F or larger), which remove central thrombus efficiently but may be difficult to advance into distal vessels. A combined strategy, using a large-bore catheter first for central thrombus and a small-bore catheter subsequently for residual distal thrombus, is used in clinical practice, but its safety and effectiveness have not been systematically evaluated in a prospective study.

Objective This multicentre prospective observational cohort study will compare the safety and short-term effectiveness of three catheter-based aspiration strategies in adults with intermediate-high-risk acute PE: small-bore aspiration alone, large-bore aspiration alone, and combined large-bore plus small-bore aspiration.

Study design

Consecutive patients scheduled to undergo percutaneous catheter aspiration thrombectomy as part of routine care at five participating hospitals in China are screened and enrolled after providing written informed consent. Participants are assigned to one of three cohorts according to the catheter strategy actually used during the index procedure; the strategy is selected by the treating physician according to routine clinical practice and is not allocated by the study protocol.

Data collection Baseline demographic, clinical, laboratory, CTPA, and echocardiographic data are collected before the procedure. Procedural data include angiographic findings, technique used, procedure and fluoroscopy times, and intraoperative blood loss. Clinical assessments are performed at 24 hours, 48 hours, and 7 days (or before discharge), with follow-up visits (clinic or telephone) at 30 +/- 7 days and 90 +/- 14 days. All imaging and laboratory tests are performed as part of standard care; the study requires no additional invasive procedures or examinations.

Co-primary endpoints

(1) The composite rate of major adverse events within 7 days after the procedure. (2) The change in the right ventricular to left ventricular (RV/LV) diameter ratio on CTPA from baseline to 48 hours after the procedure, measured by an independent core laboratory.

Statistical analysis Approximately 225 participants will be enrolled (about 75 per cohort). The co-primary effectiveness endpoint will be analysed by analysis of covariance adjusted for baseline RV/LV ratio; the composite safety endpoint will be analysed using logistic regression or Cox proportional hazards models. Non-inferiority of the combined strategy versus large-bore aspiration alone will be assessed for the composite major adverse event endpoint, with a pre-specified non-inferiority margin of 8%, together with a superiority assessment for the change in RV/LV ratio. Baseline imbalances will be addressed by multivariable regression and, as sensitivity analyses, by propensity score matching or inverse probability of treatment weighting. Subgroup analyses by risk category, thrombus distribution, age, sPESI, and VTE-BLEED score, and multiplicity adjustment using Bonferroni or Benjamini-Hochberg methods, are pre-specified. Missing primary endpoint data will be handled by multiple imputation. An independent data and safety monitoring board will perform an interim safety review when 50% of the planned enrolment is reached.

Expected impact The results are expected to inform clinical selection of aspiration catheter size and strategy in intermediate-high-risk acute PE, and to support standardisation of percutaneous interventional management.

Tipo de estudo

Intervencional

Inscrição (Estimado)

225

Estágio

  • Não aplicável

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 18 to 80 years.
  • Acute pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA).
  • Interval from symptom onset to diagnosis of 14 days or less.
  • Intermediate-high-risk PE according to the 2025 Chinese guideline and ESC risk stratification: simplified Pulmonary Embolism Severity Index (sPESI) of 1 or greater; imaging evidence of right ventricular dysfunction (CTPA RV/LV diameter ratio >= 1.0, or echocardiographic right ventricular dilatation or hypokinesia); and troponin I or T above the upper limit of normal.
  • Eligible for percutaneous catheter-directed intervention: contraindication to, or failure of, systemic thrombolysis, or clinical deterioration during anticoagulation therapy.
  • Thrombus visible in the main pulmonary artery and/or lobar arteries on CTPA.
  • Provision of written informed consent.

Exclusion Criteria:

  • Haemodynamic instability at enrolment: cardiac arrest; need for ongoing cardiopulmonary resuscitation; or systolic blood pressure below 80 mmHg for more than 15 minutes unresponsive to fluid resuscitation and vasopressors.
  • Active bleeding; known coagulopathy (INR > 2.0 or platelet count < 50 x 10^9/L); intracranial haemorrhage within the previous 90 days, or intracranial tumour or vascular malformation; major surgery, major trauma, or gastrointestinal bleeding within the previous 30 days; known heparin allergy or history of heparin-induced thrombocytopenia.
  • Planned catheter-directed thrombolysis or systemic thrombolysis.
  • Known chronic thromboembolic pulmonary hypertension; severe left ventricular dysfunction (LVEF < 30%); severe valvular heart disease (moderate-to-severe aortic stenosis or mitral regurgitation); end-stage renal disease (eGFR < 30 mL/min/1.73 m2 or dialysis dependence); pregnancy or breastfeeding.
  • Anatomical contraindications: intracardiac or pulmonary arterial mass on CTPA or ultrasound suggesting tumour or infective embolus; severe stenosis or occlusion of the inferior vena cava or the iliofemoral venous route.
  • CTPA image quality inadequate for independent core laboratory reading.
  • Expected survival of less than 6 months due to severe comorbidity (for example, advanced malignancy); inability or unwillingness to complete the follow-up schedule.
  • Participation in another clinical study that could interfere with endpoint assessment; any other condition that, in the investigator's judgement, makes participation inappropriate.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Small-Bore Catheter Aspiration Group

Participants treated with a small-bore (8-12 F) percutaneous aspiration catheter system alone during the index procedure, as selected by the treating physician according to routine clinical practice.

Continuous or intermittent vacuum aspiration through a small-bore (8-12 F) catheter positioned in the pulmonary arteries to remove thrombus. Catheter selection, access site, and aspiration technique follow the treating centre's standard practice.

Comparador Ativo: Large-Bore Catheter Aspiration Group

Participants treated with a large-bore (16 F or larger) percutaneous aspiration/mechanical thrombectomy system alone during the index procedure, as selected by the treating physician according to routine clinical practice.

Mechanical aspiration-thrombectomy using a large-bore (16 F or larger) catheter system positioned in the pulmonary arteries to remove central thrombus. Device selection and technique follow the treating centre's standard practice.

Comparador Ativo: Combined Large-Bore Plus Small-Bore Catheter Aspiration Group

Participants treated sequentially with a large-bore catheter to remove central thrombus followed by a small-bore catheter to address residual distal thrombus during the index procedure, as selected by the treating physician according to routine clinical practice.

Sequential use of a large-bore (16 F or larger) catheter to debulk central thrombus, followed by a small-bore (8-12 F) catheter to aspirate residual distal thrombus within the same procedure.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Composite Major Adverse Events Within 7 Days After the Procedure
Prazo: 7 days after the index procedure
7 days after the index procedure
Change in Right Ventricular to Left Ventricular (RV/LV) Diameter Ratio on CTPA From Baseline to 48 Hours After the Procedure
Prazo: Baseline and 48 hours after the index procedure
Baseline and 48 hours after the index procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de novembro de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2030

Conclusão do estudo (Estimado)

31 de dezembro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

4 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de outubro de 2026

Primeira postagem (Real)

13 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • WHSH-PE-2026-01

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .